KIMS
Krishna Institute of Medical Sciences share price & financials
- Price
- ₹802.95
- Market cap
- ₹34.1k Cr
- Sector
- Healthcare
- Calls analysed
- 7
Krishna Institute of Medical Sciences Limited Q1 FY27
What went well
- Total revenue of INR 1,196 crore, a growth of 36.1% year-on-year and 10.3% quarter-on-quarter.
- EBITDA of INR 240 crore, a growth of 20.1% year-on-year and 10.9% quarter-on-quarter.
- QIP successfully raised INR 1,500 crores, with INR 1,100 crores utilized to reduce debt.
What to watch
- PAT at INR 37 crores in Q1 FY27, a significant decrease from INR 85 crore in Q1 FY26.
- Consolidated EPS for FY26 showed a degrowth of 2.3% on quarter-on-quarter basis, which is an unusual comparison for an annual figure.
What Krishna Institute of Medical Sciences Limited does
Krishna Institute of Medical Sciences (KIMS) operates a chain of tertiary and quaternary care multi-specialty hospitals, treating patients across specialties including cardiology, neurosciences, oncology, orthopedics, nephrology/urology and organ transplantation (heart, lung, liver, kidney). It earns revenue from inpatient and outpatient hospital services — surgeries, treatments, diagnostics and critical care — billed to patients, insurers and government health schemes such as Aarogyasri. The company grows its hospital network through owned/greenfield facilities, asset-light Operations & Management (O&M) contracts, and acquisitions of existing hospitals. It began with a single hospital in Nellore in 2000 and has since expanded into Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala.
- Overall bed capacity (network, incl. pipeline)
- 8,600+ beds
- Operational beds (FY26, group)
- 4,852 beds
- Geographic footprint
- Hospitals across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala; entering Tamil Nadu (Chennai)
- Workforce
- 20,400+ employees
- ECMO machines
- 18 machines — largest ECMO program in India
- Robotic surgery systems
- 4-Arm HD da Vinci robotic surgical systems installed at Secunderabad, Kondapur, Nagpur and Kannur
Guidance record · Q1 FY27
what the last two calls moved 20 tracked 4 delivered 4 missed 12 open- Thane Unit Breakeven delivered said Q2 FY26 Promised: Achieve breakeven in the next 2 months (i.e., by end of Q3 FY26). Q1 FY27: Achievement confirmed and strengthened. After a seasonally weak Q1, the Thane unit reported ₹21 crore revenue with a 10% EBITDA margin in July, demonstrating a solid ramp-up.
- Peak Net Debt missed said Q4 FY25 Promised: Peak net debt anticipated to reach about ₹2,100 crores by the end of FY26. Q1 FY27: This promise for FY26 was definitively missed, with debt peaking at ₹3,250 cr before the QIP.
- Debt to EBITDA Ratio on track said Q3 FY25 Promised: Maintain ratio below 2.0x over the next 2 years. Q1 FY27: Following a ₹1,100 cr debt repayment from QIP proceeds, gross debt is down to ₹2,400 cr. With LTM EBITDA at ₹876 cr and cash of ₹505 cr, the net debt/EBITDA ratio is now ~2.16x, a significant improvement from ~3.6x and on track to meet the 2.0x target.
All 20 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 29.8%, net profit up 11.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 363 | 348 | 346 | 373 | 430 +18% | 442 +27% | 456 +32% | 484 +30% |
| EBITDA | 111 | 103 | 109 | 98 | 112 +1% | 128 +24% | 130 +19% | 118 +20% |
| Net profit | 72 | 76 | 94 | 59 | 64 −11% | 72 −5% | 66 −30% | 66 +12% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +1.8% 1Y
1Y: ₹755.65 on 10 Sept 2025 → ₹768.95. High ₹850.65 (3 Jul 2026), low ₹582.1 (23 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- −3.0%
- 4 Aug
- Q4 FY26
- −5.9%
- 18 May
- Q3 FY26
- +8.7%
- 9 Feb
- Q2 FY26
- −3.7%
- 10 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue fell 3.9% a year over 3 years, FY23 to FY26. Operating margin narrowed to 27.5%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹1.9k Cr | ₹1.2k Cr | ₹1.4k Cr | ₹1.7k Cr |
| Operating profit | ₹544 Cr | ₹363 Cr | ₹417 Cr | ₹468 Cr |
| Operating margin | 28.4% | 29.7% | 30.1% | 27.5% |
| Interest | ₹26 Cr | ₹3 Cr | ₹24 Cr | ₹79 Cr |
| Depreciation | ₹104 Cr | ₹58 Cr | ₹58 Cr | ₹87 Cr |
| Net profit | ₹341 Cr | ₹235 Cr | ₹303 Cr | ₹261 Cr |
| Net margin | 17.8% | 19.2% | 21.9% | 15.3% |
| Cash from operations | ₹271 Cr | ₹262 Cr | ₹294 Cr | ₹292 Cr |
| Free cash flow | ₹150 Cr | ₹-58 Cr | ₹-12 Cr | ₹-63 Cr |
| ROCE | 23.0% | 17.0% | 16.0% | 13.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹78 Cr | ₹80 Cr | ₹80 Cr | ₹80 Cr | ₹80 Cr | ₹80 Cr |
| Reserves | ₹830 Cr | ₹1.3k Cr | ₹1.6k Cr | ₹1.8k Cr | ₹2.2k Cr | ₹2.3k Cr |
| Borrowings | ₹131 Cr | ₹18 Cr | ₹4 Cr | ₹326 Cr | ₹3.2k Cr | ₹1.5k Cr |
| Other liabilities | ₹175 Cr | ₹173 Cr | ₹177 Cr | ₹204 Cr | ₹1.2k Cr | ₹330 Cr |
| Total liabilities | ₹1.2k Cr | ₹1.6k Cr | ₹1.8k Cr | ₹2.4k Cr | ₹6.6k Cr | ₹4.3k Cr |
| Fixed assets | ₹582 Cr | ₹592 Cr | ₹612 Cr | ₹674 Cr | ₹4.6k Cr | ₹1.5k Cr |
| Capital work in progress | ₹8 Cr | ₹13 Cr | ₹16 Cr | ₹292 Cr | ₹573 Cr | ₹116 Cr |
| Investments | ₹213 Cr | ₹542 Cr | ₹826 Cr | ₹1.1k Cr | ₹98 Cr | ₹1.5k Cr |
| Other assets | ₹411 Cr | ₹422 Cr | ₹358 Cr | ₹368 Cr | ₹1.3k Cr | ₹1.1k Cr |
| Total assets | ₹1.2k Cr | ₹1.6k Cr | ₹1.8k Cr | ₹2.4k Cr | ₹6.6k Cr | ₹4.3k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +2.77 pp while promoters trimmed −1.62 pp. The shareholder count shrank 13% to 94,730.
- Promoters
- 32.5%
- FIIs
- 14.8%
- DIIs
- 34.4%
- Public
- 18.3%
Since Jun 2025
- DIIs +2.77 pp
- Promoters −1.62 pp
- FIIs −0.79 pp
How it drifted, 12 quarters
Over this window promoters fell from 38.9% to 32.5% — −6.4 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 38.9%, FIIs 14.2%, DIIs 34.8%, Public 12.1%.Dec '23: Promoters 38.8%, FIIs 15.3%, DIIs 34.2%, Public 11.7%.Mar '24: Promoters 38.8%, FIIs 16.7%, DIIs 33.1%, Public 11.3%.Jun '24: Promoters 38.8%, FIIs 17.8%, DIIs 32.1%, Public 11.2%.Sep '24: Promoters 38.8%, FIIs 15.8%, DIIs 32.3%, Public 13.0%.Dec '24: Promoters 38.8%, FIIs 15.7%, DIIs 32.0%, Public 13.4%.Mar '25: Promoters 38.8%, FIIs 15.4%, DIIs 31.9%, Public 13.8%.Jun '25: Promoters 34.1%, FIIs 15.5%, DIIs 31.6%, Public 18.7%.Sep '25: Promoters 34.1%, FIIs 15.0%, DIIs 32.1%, Public 18.7%.Dec '25: Promoters 34.1%, FIIs 14.3%, DIIs 32.7%, Public 18.9%.Mar '26: Promoters 34.1%, FIIs 14.6%, DIIs 32.5%, Public 18.8%.Jun '26: Promoters 32.5%, FIIs 14.8%, DIIs 34.4%, Public 18.3%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Mirae Asset Small Cap Fund Mutual fund newly disclosed 1.04% held
- Kotak Small Cap Fund Mutual fund +0.59 pp 3.61% held
- Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund Mutual fund +0.37 pp 1.95% held
- HDFC Life Insurance Company Limited Insurer +0.28 pp 1.29% held
- Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund Mutual fund +0.17 pp 4.50% held
- Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110 Insurer +0.13 pp 1.57% held
- Bharas Ventures LLP newly disclosed 0.00% held
The same filing shows 11 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Krishna Institute of Medical Sciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Bhaskara Rao Bollineni | 25.02% | −1.25 pp |
| Bluebridge Capital Private Limited | 5.76% | −0.29 pp |
| SBI Small Cap Fund Mutual fund | 5.17% | −0.72 pp |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund Mutual fund | 4.50% | +0.17 pp |
| HDFC Small Cap Fund Mutual fund | 3.98% | −0.37 pp |
| Bollineni Seenaiah Naidu | 3.93% | −0.19 pp |
| Kotak Small Cap Fund Mutual fund | 3.61% | +0.59 pp |
| Invesco India Flexi Cap Fund Mutual fund | 3.54% | unchanged |
| Amansa Holdings Private Limited FPI fund | 2.24% | −0.10 pp |
| Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund Mutual fund | 1.95% | +0.37 pp |
| Lilac Investments Limited | 1.87% | −0.09 pp |
| SBI Life Insurance Co. Ltd Insurer | 1.71% | −0.21 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in KIMS
Filings to Aug 2026
0 new, 4 added, 3 trimmed, 0 sold out — net −1.44 L shares (−0.3%).
- Held by funds
- ₹3.5k Cr
- 16 schemes
- Biggest holder
- HDFC Small Cap Fund
- ₹896 Cr · 2.1% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| HDFC Small Cap Fund HDFC Mutual Fund | ₹896 Cr | held | Jul '23 |
| SBI Smallcap Fund SBI Mutual Fund | ₹831 Cr | held | Jun '23 |
| SBI MultiCap Fund SBI Mutual Fund | ₹491 Cr | held | Jun '23 |
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹462 Cr | held | May '23 |
| HDFC Hybrid Equity Fund HDFC Mutual Fund | ₹338 Cr | held | Nov '23 |
| SBI Healthcare Opportunities Fund SBI Mutual Fund | ₹101 Cr | held | Nov '22 |
| SBI ELSS Tax Saver Fund SBI Mutual Fund | ₹100 Cr | held | Jun '26 |
| HDFC Pharma and Healthcare Fund HDFC Mutual Fund | ₹79 Cr | held | Nov '23 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
4 added, 3 trimmed — net −1.44 L shares (−0.3%)
- Funds are sitting on
- +95%
- vs est. average cost
- Held by funds
- ₹3.5k Cr
- 16 schemes · ≈ 11% of the company
- Biggest holder
- HDFC Small Cap Fund
- ₹896 Cr · 2.1% of that fund
- Longest holder
- Nippon India Nifty Smallcap 250 Index Fund
- 4y 6m · since Mar '22
Shares held by these funds +32%
Aug '23 4.49 cr shares Jul '26
What the price assumes
Growth trapTo justify its price of ₹769, this stock must grow earnings at 52% every year for 7 years. Our analysis caps realistic growth at ~-5%. At that growth it is worth ₹45 — downside of 94%.
- Growth the price implies
- 52.0% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -7.0% a year
- net profit, FY23–FY26 · EPS -4.7%
- The gap
- 0.6 pp
- -94% downside if it only repeats history
All earnings calls (7)
Read the Q1 FY27 call →Learn to analyse Krishna Institute of Medical Sciences Limited
Guides on how to read this kind of business and the numbers that matter.